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ABSTrACT
The risk of severe acute respiratory distress syndrome 
associated with coronavirus-2 (SArS-CoV-2) to ma-
ternal and newborn health has yet to be determined. 
Several studies showed that pregnancy with gesta-
tional diabetes increased the risk of maternal illness, 
but cases of gestational diabetes, preeclampsia and 
preterm birth have been reported rarely. reports in-
dicated placental infection and vertical transmission 
of COVID-19 were uncommon. Interestingly, despite 
the lack of SArS-CoV-2 placental infection, there were 
many records of major abnormalities in placental 
morphology. Continued research into offsprings of 
pregnant women with gestational diabetes infected 
with SArS-CoV-2 was vitally necessary. This study 
showed the impact of COVID infections on the fetus 
and the newborn in gDM pregnancy. There were very 
few data considering this subject and therefore, the 
findings have nowadays very debatable value. How-
ever, it’s worthwhile to show the scientific community 
that nowadays we have no proof that COVID infection 
has a significant impact on pregnancy and the fetus. 
(Clin Diabetol 2020; 9; 6: 367–371)
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Introduction 
Severe acute respiratory distress syndrome associ-
ated with coronavirus-2 (SARS-CoV-2), was an etiologi-
cal agent of Coronavirus disease 2019 (COVID-19). It 
was first identified in Wuhan, China, in December 2019 
and is now a global pandemic. To date, more than 
4 million cases and 300,000 deaths have been reg-
istered by the World Health Organisation. There has 
been a significant increase in awareness of the genetic, 
virological, epidemiological, and clinical aspects of 
COVID-19, but there are far fewer studies explaining 
the risks and unique impact of COVID-19 on pregnant 
females with gestational diabetes and their newly born 
infants. In this study, both peer-reviewed and non-peer-
reviewed preprints were included in order to identify 
the most up-to-date information.
Pregnancy with gestational diabetes increases the 
risk of adverse obstetric and neonatal outcomes due 
to many respiratory viral infections. The maternal im-
mune system is altered during pregnancy in order to 
prevent the rejection of the fetus and to contribute to 
the development of the fetus [1]. Some viral infections 
cause more serious or prolonged illness in pregnant 
women with gestational diabetes [2]. COVID-19 has 
resulted in elevated rates of abortion, infant mortality 
and preterm delivery [3]. Multiple influenza studies 
have shown an increased risk of maternal morbidity 
and mortality relative to non-pregnant women. On the 
other hand, the majority of results for pregnant women 
with gestational diabetes infected with SARS-CoV-2 
[5–53] do not vary from the general population. Fever 
is the most common symptom of COVID-19 in these 
patients, but many also experience cough, shortness 
of breath, and diarrhea. Occasionally serious infec-
tions involved mechanical ventilation [2–46] but rarely 
resulted in death [4, 5]. 
COVID in pregnant women  
with gestational diabetes
Although the majority of COVID infections in 
pregnant women with gestational diabetes were 
mild, data indicated substantial placental pathology 
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in SARS-CoV-2 pregnancy despite lack of detectable 
or very low levels of SARS-CoV-2 mRNA or protein 
[4–43]. There were, however, case studies suggesting 
COVID-19 virons in syncytio-trophoblasts in placental 
villous when examined by the electron microscopy 
[6–8] or (PCR) [5, 28, 36].  The significant questions 
that remains unanswered are, whether SARS-CoV-2 
replicates in the placenta, whether it is the cause of the 
reported placenta abnormalities and, whether SARS-
CoV-2 is an “innocent bystander.” It is also important 
to note that the identified placenta abnormalities occur 
mainly in women who are asymptomatic or have mild 
to moderate illness, indicating that these defects are 
not necessarily due to severe COVID disease.
Placenta abnormalities  
in diabetic women
The placenta abnormalities identified in an infected 
diabetic pregnant women with SARS-CoV-2 include 
diffuse perivil fibrin, fetal vascular malperfusion in 
fetal vessels, choriohemangioma, maternal vascular 
malperfusion, and multifocal infarctions [17, 26, 36]. 
In some cases, SARS-CoV-2 has been found in the pla-
centa [5, 17, 28, 36]. Lack of controls and non-specific 
staining issues [16] complicate the interpretation of 
these findings in some of these studies. Importantly, 
the vast majority of placenta cases were negative for 
SARS-CoV-2 as calculated by PCR [12, 22, 26, 27, 36, 
41, 43]. The anomalies observed in placenta pathology 
therefore indicated that the placenta was vulnerable 
to maternal COVID-19 disease, even in the absence of 
infection, because in many cases these disorders may 
be due to maternal co-morbidities such as hyperten-
sion, preeclampsia, and gestational diabetes. There is, 
therefore, a vital need for thorough systematic studies 
to determine the prevalence of infection and replication 
of SARS-CoV-2 in the placenta and its connection with 
placenta abnormalities. 
Easy vertical transmission? 
It still remains to be seen whether SARS-CoV-2 
can be transferred from a diabetic pregnant woman 
to her fetus, a process called vertical transmission. Im-
portantly, the transmission is predicted to have various 
effects over the three trimesters of pregnancy. Transpla-
cental transmission of the virus typically increases with 
advanced gestational age, while there is a decreases in 
the incidence of fetal injuries from embryopathy and 
embryo/fetal death in the first trimester, from fetal 
infection and immune response during the second 
and third trimesters. Unlike many other viral diseases, 
viremia in SARS-CoV-2 is observed in just 1% of symp-
tomatic patients and is usually mild and transient [19].
Effect of COVID-19 on newly born infants
Most of the case reports documented that, the 
birth of a full term baby to COVID-19 positive moth-
ers with mild to moderate illness is not carrying any 
significant risk to the baby itself [8–53]. Preterm births, 
on the other hand, are fairly common in women with 
severe illness, although there are sporadic reports of 
spontaneous preterm births [9–53]. Spontaneous abor-
tion has also been reported twice in early pregnancy 
[5, 45] and fetal death has been reported 6 times [13, 
18, 23, 24]. Case reports of newborns with symptoms 
requiring NICU admission for tachypnea, tachycar-
dia, fever, gastrointestinal symptoms, and signs of 
CT pulmonary infection [2, 7, 12, 27, 41, 48, 52, 53] 
were reported; with 2 of 5 had NP swabs positive for 
SARS-CoV-2. Interestingly, some symptomatic infants 
tested negative for SARS-CoV-2. In one case, a positive 
SARS-CoV-2 infant born at 31 weeks of age needed 
resuscitation and was diagnosed with pneumonia, but 
the authors confirmed that they suspected sepsis with 
Enterobacter [52]. Thus, with the exception of these 
unusual cases, neonates were born healthy to infected 
mothers ofwith SARS-CoV-2. However, it has yet to be 
known whether infection at an earlier stage would have 
a significant effect on neonatal health and whether it 
results in long‐term outcomes.
Actual mode of transmission 
Newborns may be infected by viral infection 
from mother either directly by the virus through 
vertical transmission or passively, by the maternal 
reaction to the virus. Considerable evidence indicates 
the absence of vertical transmission of SARS-CoV-2. 
Multiple newborns were screened for SARS-CoV-2 at 
delivery and viral RNA was not found in cord blood, 
throat and nasopharyngeal swabs, urine, and feces 
[5, 51]. Amniotic fluid samples were also obtained 
from positive COVID pregnant mothers and were 
mainly screened negative for SARS-CoV-2 [5–49]. 
Neonatal testing, 24 hours or more after birth, have 
rarely been confirmed positive for the virus [27–52], 
but due to delays in testing, these infants may have 
already been infected after birth. There was one case 
report of COVID-19 neonates at birth, but the baby 
was symptom free with, perhaps, the exception of 
some minor initial nursing problems [28]. In addition, 
despite cautious isolation, the baby born at 33 weeks 
of age tested positive after 16 hours and again after 
48 hours post-partum [2]. The authors indicated that 
this infant may have been infected either during the 
delivery of the ceasarean or in the uterus. The baby 
needed admission to the NICU for low Apgar scores 
and ventilator support.
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Antibodies were found in neonatal blood
Most babies in these studies were delivered by 
a cesarean section, and it is possible that newborns 
could potentially be contaminated during vaginal deliv-
ery. Vaginal swabs, however, were screened negative at 
37 weeks of caesarean section delivery [12] and nega-
tive for SARS-CoV-2 in 6 women at hospital admission 
[45]. Intriguingly, despite the absence of virus present 
in neonate at birth, antibodies have been detected 
in neonatal tissue [51]. In particular, IgM has been 
documented to be elevated indicating fetal exposure to 
the uterine virus [51]. It is important to note that IgM 
antibody testing results in a high risk of false-positive 
[19] but these findings indicate that ongoing neonatal 
antibody testing can be useful. 
Extracellular vesicles confer viral  
resistance to receptor cells
Overall, there is little evidence of vertical transmis-
sion in the majority of cases of positive COVID-19 birth. 
The fact that viremia is present in 1% of symptomatic 
patients and is usually mild and temporary may play 
a role [42]. However, other processes are likely to be 
just as important or more important in the defense of 
the fetus against vertical transmission. Maternal-fetal 
interface barriers protect the fetus from infection. For 
example, the syncytiotrophoblasts organize the im-
mune response to infection and also act as a physical 
barrier to the viral passage [29, 47]. Immune cells in 
the placenta also have anti-viral potential [47]. Finally, 
previous studies have shown that trophoblast-derived 
extracellular vesicles containing a special group of 
miRNAs, expressed as chromosome 19 miRNA clusters, 
confer viral resistance to receptor cells suggesting 
a paracrine role that allows contact between placental 
cells to control their immunity to viral infections [10].
The ability of the virus to replicate and infect the 
placenta is also dependent on the virus. In the case 
of SARS-CoV-2, the entry of cells requires the binding 
of the spike protein to ACE2 [15]. The virus is then 
produced by cellular proteases such as TMPRSS2 [15] 
and possibly cathepsin B/L7 [37] and furin [6]. Utilizing 
recently reported single-cell RNAseq results, researchers 
have observed robust ACE2 activity in the placenta [21, 
37] though not in TMPRSS2 [37]. Two studies, using 
single nucleotide RNAseq or single-cell RNAseq, were 
recently performed during gestation and found expres-
sion of ACE2 but either no or very low levels of TMPRSS2 
were detected in the placenta [3, 32]. There has been 
no systematic assessment of the presence and role of 
other proteases that lead to viral entry and replication 
in the placenta cell. ACE2 was observed by 133 IHC in 
syncytio-trophoblast, cyto-trophoblast, endo-thelial 
and smooth muscles of the blood vessels [40].
Interestingly, ACE2 is involved in placentation, 
including the migration of trophoblasts, vascular 
remodeling, and maternal vasodilation [33, 39]. 
Complications such as abortion, ectopic pregnancy, 
and preeclampsia have also been implicated in ACE2 
[40]. Therefore, if SARS-CoV-2 affects the expression 
of ACE2 in the placenta as shown by SARS-CoV-1 in 
the lung [20], there is a risk for placental defects and 
complications of pregnancy. The existence of ACE2 in 
the placenta could mean that there is a capacity to 
bind COVID-19 to cause viral infection, but there are 
mechanisms that underlie SARS-CoV-2’s failure to infect 
and replicate in the placenta are unknown.
Conclussion 
 Vertical transmission of SARS-CoV-2 is consid-
ered unlikely at this time but there appears to be consid-
erable potential for SARS-CoV-2 to affect the placental 
function and fetal development. Continued research is, 
therefore, needed focusing especially on the detection 
of SARS-CoV-2 at early gestational time points. Finally, 
careful longitudinal studies with adequate controls 
are needed before any conclusions about COVID-19’s 
maternal or neonatal effects are drawn.
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